trial

Improving Accessibility and Personalization of CR for Schizophrenia

NCTId NCT03576976
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 67 (actual)
Sponsored by New York State Psychiatric Institute, Washington Heights Community Service
Primary completion 2020-12-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
67 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2018-07-16
Primary completion
2020-12-31
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Cognitive Remediation

Sponsors

New York State Psychiatric Institute, Washington Heights Community ServiceLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Alice Medalia, PhDPrincipal Investigator

Sites

7 total
Brooklyn, United StatesBrooklyn, United StatesBrooklyn, United StatesNew York, United StatesNew York, United StatesOrangeburg, United StatesQueens Village, United States

Facts & assertions

4 sourced
Enrollment
67
Phase
NA
Primary Completion Date
2020-12-31
Status
COMPLETED
relationships
The graph out of here
drug
Cognitive Remediation
drug
lead_sponsor
New York State Psychiatric Institute, Washington Heights Community Service
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Alice Medalia, PhD
person